There is a narrow difference between the therapeutic and toxic ranges of cardiac glycosides. The availability in the past decade of radioimmunoassays for accurate measurement of these glycosides has resulted in an improved understanding of their pharmacokinetics and clinical use. Despite these advances, however, digitalis toxicity is still a common problem in infants and children.
Increased levels of urinary β2-microglobulin (β2M) have been used as a marker of proximal tubular dysfunction in human neonates. To assess the value of β2M in the detection of early stages of tubular damage caused by gentamicin, renal handling of β2M was studied sequentially in 18 gentamicin-treated neonates with idiopathic respiratory distress syndrome (mean birth weight 1,781 g, mean gestational age 33.7 weeks) during the first 7 days of life. These data were compared with those obtained from 10 control infants matched for gestational and postnatal ages. In addition, follow-up studies of renal function were conducted in 14 of 18 study infants 1 week after termination of therapy, on day 14 postpartum. The ( ± SD) fractional tubular excretion of β2M (FEβ2M) tended to decrease significantly in the control infants from 10.3 ± 1% on day 1 to 6.5 ± 0.8% on day 7 postpartum (p < 0.05). In infants treated with gentamicin, the mean FEβ2M rose from 10.5 ± 2% on day 1 to 17.1 ± 1%on day 7 (p < 0.01), followed by a decrease to 8.2 ± 0.5% over the next 7 days (p < 0.001). Compared with the control infants, values for the infants receiving gentamicin were significantly higher on postpartum days 3,5, and 7 (p < 0.001). No significant differences in serum creatinine, creatinine clearance, or fractional tubular excretion of sodium were observed between the two groups during the study period. These results suggest that administration of gentamicin with a penicillin antibiotic to preterm infants with idiopathic respiratory distress syndrome is associated with increased FEβ2M and that the FEβ2M may serve as a useful indicator of tubular dysfunction in infants treated with gentamicin.
Continuous monitoring of v i t a l s i g n s , e . g . temperature, blood pressure, heart and r e s p i r a t i o n r a t e s , and E C G , f o r the care of c r i t i c a l l y s i c k infants has become an established hospital routine. W e have compared various non-invasive and invasive continuous Pa02 monitors with a r t e r i a l blood Pa02 levels and find t h a t there i s a considerable c o r r e l a t i o n between the values obtained by d i f f e r e n t procedures. Continuous monitoring procedures permit b e t t e r evaluation of the p a t i e n t than skin c o l o r , ECG monitoring o r c l i n i c a l observation.I t s immediate a v a i l a b i l i t y a t bedside and the capacity t o detect i r r e g u l a r i t y in oxygen supply i s of major c l i n i c a l advantage. These devices help in preventing t h e e f f e c t s of hyperoxemia and hypoxemia. S t a b i l i z a t i o n of s i c k infants can be achieved rapidly without repeated a r t e r i a l blood sampling f o r Pa02 determinations. The r e s u l t s suggest t h a t these continuous Pa02 monitors (invasive o r non-invasive) may be a b l e t o eliminate or minimize conditions l i k e bronchopulmonary dysplasia, r e t r o l e n t a l f i b r o p l a s i a and brain damage due t o lack of oxygen during neonatal development. INTRAUTERINE FETAL RESUSCITATION WITH TERBUTALINENer esh A. Te a n i , Uma L. Verma, S amali Chatter ee.1451 Spo:. by P l a t i n J. Collipp. NassavlCty Med C t r , i l t h S c i C t r , SUNY a t Stony Brook, Dept. of Ob/Gyn, East Meadow, NY Cases of i n t r a p a r t a l f e t a l d i s t r e s s from any cause s u s t a i n f u r t h e r hypoxia during u t e r i n e contractions due t o t h e concomit a n t reduction i n u t e r i n e blood flow during u t e r i n e a c t i v i t y . Therapeutic reduction of u t e r i n e a c t i v i t y should, t h e r e f o r e , res u l t i n recovery of f e t a l h e a r t r a t e (FHR) and f e t a l a c i d o s i s , and t h e b i r t h of a neonate i n a b e t t e r s t a t e of owgenation and acid-base balance. Towards t h i s , t e r b u t a l i n e 250 Ug subcutaneously was i n j e c t e d i n p a t i e n t s with evidence of f e t a l d i s t r e s s . A l l 1 1 p a t i e n t s showed ominous FHR changes. I n 2 of t h e s e , f e t a l s c a l p blood pH (FSB-pH) was not t e c h n i c a l l y possible. I n 2 , t h e FSB-pH was b 7.25. The remaining 7 p a t i e n t s showed FSB-pH 4 7.25.Results: Where adequate FHR t r a c e was a v a i l a b l e , 9/10 pat i e n t s showed marked reduction t o cessation of u t e r i n e a c t i v i t y , and complete o r p a r t i a l recovery of ominous FHR changes. FSB-pH was compared t o t h e mid-point of t h e umbilical vein and a r t e r y pH's. I n t h e 2 cases where t h e o r i g i n a l FSB-pH was b 7.25, no change was seen. However, i n cases with FSB-pH 5 7.25, a s i gn i f i c a n t improvement from a mean of 7.180 + .038 t o 7.270 2 .066 (P = 4 .005) was seen. No major s i d e e f f e d s were noted. ST of AP l i p . e x t . meas...
To determine the effect of dialysate osmolarity on peritoneal dialysis drug transfer, peritoneal dialysis clearances of theophylline, phenobarbital, and tobramycin were determined in 10 rabbits using dialysate containing 1.5 and 4.25% glucose. Urea and creatinine clearances were also obtained for comparison. Under similar dialysis conditions, the peritoneal clearances of the three drugs remained unchanged for the two types of dialysate. In contrast, the peritoneal clearances of urea and creatinine were significantly higher with the use of 4.25 % glucose dialysate (p < 0.001). Thus, peritoneal dialysis clearances of theophylline, phenobarbital and tobramycin are not significantly affected by hypertonicity-induced ultrafiltration during acute peritioneal dialysis.
scite is a Brooklyn-based organization that helps researchers better discover and understand research articles through Smart Citations–citations that display the context of the citation and describe whether the article provides supporting or contrasting evidence. scite is used by students and researchers from around the world and is funded in part by the National Science Foundation and the National Institute on Drug Abuse of the National Institutes of Health.
customersupport@researchsolutions.com
10624 S. Eastern Ave., Ste. A-614
Henderson, NV 89052, USA
This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Copyright © 2024 scite LLC. All rights reserved.
Made with 💙 for researchers
Part of the Research Solutions Family.